Benjamin Bell, Ph.D., CFA is a Senior Analyst at Catalio Capital Management, LP, focusing on public equity investments across Clinical Therapeutics.
Prior to joining Catalio, Ben was a Biotech Associate on the Health Sciences team at T. Rowe Price, where he was responsible for recommending and monitoring public equity positions across therapeutics companies. Earlier in his career, Ben led a drug discovery research team for 3 years and participated in the Catalio internship program.
Ben earned his Ph.D. in genetics and neuroscience from the Johns Hopkins School of Medicine, and his B.S. in biochemistry from Northeastern University. He also has earned the Chartered Financial Analyst designation.